Elevated glutaminase and glutamate levels following mTOR (mammalian target of rapamycin) kinase inhibitor treatment promoted GBM survival while combined inhibition of mTOR kinase and glutaminase resulted in massive synergistic tumor cell death and growth inhibition. This evidence concerns the gene GLS and glioblastoma.